X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (78) 78
Newspaper Article (73) 73
Publication (10) 10
Book Chapter (3) 3
Book Review (3) 3
Book / eBook (2) 2
Conference Proceeding (2) 2
Dissertation (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (42) 42
index medicus (27) 27
hiv-1 - drug effects (19) 19
virology (18) 18
hiv infections - drug therapy (16) 16
viruses (16) 16
antiviral agents (15) 15
cell line (14) 14
infection (14) 14
infectious diseases (14) 14
animals (13) 13
hiv (13) 13
triazoles - pharmacology (13) 13
anti-hiv agents - pharmacology (12) 12
ccr5 receptor antagonists (12) 12
cyclohexanes - pharmacology (12) 12
hiv infections - virology (11) 11
drug resistance, viral (10) 10
immunology (10) 10
maraviroc (10) 10
molecular sequence data (10) 10
pharmacology & pharmacy (10) 10
cyclohexanes - therapeutic use (9) 9
hiv-1 - genetics (9) 9
triazoles - therapeutic use (9) 9
drug resistance (8) 8
hiv-1 - physiology (8) 8
mutation (8) 8
virus diseases (8) 8
chemistry, medicinal (7) 7
drug resistance, viral - genetics (7) 7
female (7) 7
hiv-1 (7) 7
immunodeficiency-virus type-1 (7) 7
inhibitor (7) 7
male (7) 7
microbiology (7) 7
aids (6) 6
amino acid sequence (6) 6
anti-hiv agents - therapeutic use (6) 6
efficacy (6) 6
health aspects (6) 6
human immunodeficiency virus--hiv (6) 6
receptors, ccr5 - metabolism (6) 6
research (6) 6
resistance (6) 6
viral load (6) 6
antiviral agents - pharmacology (5) 5
drug resistance, viral - drug effects (5) 5
drug therapy (5) 5
entry (5) 5
genotype (5) 5
gp120 (5) 5
hiv envelope protein gp120 - genetics (5) 5
hiv fusion inhibitors - pharmacology (5) 5
hiv fusion inhibitors - therapeutic use (5) 5
human-immunodeficiency-virus (5) 5
in-vitro (5) 5
models, molecular (5) 5
phenotype (5) 5
rats (5) 5
structure-activity relationship (5) 5
therapy (5) 5
abridged index medicus (4) 4
base sequence (4) 4
cells (4) 4
dogs (4) 4
double-blind method (4) 4
drug therapy, combination (4) 4
enzyme-linked immunosorbent assay (4) 4
federal government (4) 4
glycoproteins (4) 4
government (4) 4
hiv envelope protein gp120 - metabolism (4) 4
hiv infection (4) 4
hiv infections - immunology (4) 4
imidazoles - chemistry (4) 4
imidazoles - pharmacology (4) 4
prognostic value (4) 4
rna (4) 4
treatment outcome (4) 4
viral nonstructural proteins - antagonists & inhibitors (4) 4
viral nonstructural proteins - metabolism (4) 4
virus internalization - drug effects (4) 4
virus replication - drug effects (4) 4
acquired immune deficiency syndrome--aids (3) 3
adult (3) 3
aged (3) 3
analysis (3) 3
antiviral agents - chemistry (3) 3
area planning & development (3) 3
binding (3) 3
biochemical research methods (3) 3
biomedicine (3) 3
care and treatment (3) 3
ccr5 (3) 3
ccr5 antagonist (3) 3
cell line, tumor (3) 3
chemokines (3) 3
clinical trials as topic (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 3/2010, Volume 201, Issue 6, pp. 803 - 813
Background. The MERIT (M̄araviroc versus Ēfavir̄enz īn T̄reatment-Naive Patients) study compared maraviroc and efavirenz, both with zidovudine-lamivudine, in... 
HIV/AIDS | Tropisms | RNA | HIV | Stock options | Response rates | Viruses | Infections | Post hoc | HIV 1 | Virology | INFECTIOUS DISEASES | EFFICACY | SAFETY | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | LOPINAVIR-RITONAVIR | THERAPY | VIROLOGICAL FAILURE | RESISTANT HIV-1 | INHIBITOR | CORECEPTOR TROPISM | PLUS | Anti-HIV Agents - pharmacology | Lamivudine - administration & dosage | Cyclohexanes - pharmacology | Humans | Middle Aged | Drug Resistance, Viral | Male | Anti-HIV Agents - standards | Viral Load | Zidovudine - administration & dosage | Young Adult | Cyclohexanes - therapeutic use | Receptors, CCR5 - metabolism | HIV-1 - physiology | Adult | Female | Triazoles - standards | Viral Tropism | Drug Therapy, Combination | CCR5 Receptor Antagonists | Triazoles - therapeutic use | Antiviral Agents - pharmacology | Double-Blind Method | HIV-1 - drug effects | Treatment Outcome | Anti-Retroviral Agents | Benzoxazines - standards | Benzoxazines - therapeutic use | Triazoles - pharmacology | Adolescent | Benzoxazines - pharmacology | Cyclohexanes - standards | HIV Infections - drug therapy | Aged | Drug Combinations | Maraviroc | Patient outcomes | Physiological aspects | Dosage and administration | Genetic aspects | Research | Drug therapy, Combination | Drug therapy | HIV infection | Efavirenz | Chemokines
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2008, Volume 359, Issue 14, pp. 1442 - 1455
In key subgroups of the HIV-infected patients in the MOTIVATE 1 and MOTIVATE 2 studies, a consistent treatment benefit of maraviroc over placebo was seen at 48... 
CCR5 ANTAGONIST | MEDICINE, GENERAL & INTERNAL | EFFICACY | EXPERIENCED HIV-1-INFECTED PATIENTS | TMC125 ETRAVIRINE | ACTIVE ANTIRETROVIRAL THERAPY | DRUG-RESISTANT HIV-1 | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | HEPATITIS-C | PROGNOSTIC VALUE | Triazoles - adverse effects | Humans | Middle Aged | Receptors, CCR5 - genetics | Male | RNA, Viral - blood | Hepatitis B - blood | Viral Load | Hepatitis B - complications | Cyclohexanes - therapeutic use | HIV Infections - immunology | Ethnic Groups | HIV Envelope Protein gp41 - therapeutic use | HIV-1 - chemistry | Hepatitis C - blood | Adult | Female | Hepatitis C - complications | Cyclohexanes - adverse effects | Drug Therapy, Combination | Odds Ratio | CCR5 Receptor Antagonists | Triazoles - therapeutic use | Anti-Retroviral Agents - therapeutic use | Double-Blind Method | HIV Infections - virology | Anti-Retroviral Agents - adverse effects | Genotype | Treatment Outcome | CD4 Lymphocyte Count | HIV Fusion Inhibitors - adverse effects | HIV-1 - genetics | HIV Fusion Inhibitors - therapeutic use | HIV Infections - drug therapy | Transaminases - blood | Aged | Peptide Fragments - therapeutic use | Antiviral agents | Care and treatment | Maraviroc | Comparative analysis | Health aspects | HIV infection | Drug therapy | Drug resistance | Human immunodeficiency virus--HIV | Chemokines | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal of Molecular Medicine, ISSN 0946-2716, 6/2015, Volume 93, Issue 6, pp. 619 - 631
The ever-increasing threat of multi-drug resistant bacterial infections has spurred renewed interest in alternative approaches to classical antibiotic therapy.... 
Human Genetics | Antibiotic therapy | Antibodies | Internal Medicine | α-Gal | Drug development | Anti-Gal | Biomedicine | Group A Streptococcus | Molecular Medicine | Aptamer | Galactose-α-1,3-galactosyl-β-1,4- N -acetyl-glucosamine | Phagocytosis | M protein | Galactose-α-1,3-galactosyl-β-1,4-N-acetyl-glucosamine | MEDICINE, RESEARCH & EXPERIMENTAL | TRIALS | VACCINE | alpha-Gal | MOLECULES | GROUP-A STREPTOCOCCI | M PROTEINS | DISEASES | GENETICS & HEREDITY | PYOGENES | MONOCLONAL-ANTIBODIES | EXPRESSION | Galactose-alpha-1,3-galactosyl-beta-1,4-N-acetyl-glucosamine | EPITOPES | Aptamers, Nucleotide - pharmacology | Phagocytosis - drug effects | Acetylglucosamine - immunology | Streptococcus - immunology | Humans | Aptamers, Nucleotide - chemistry | Epitopes - pharmacology | Molecular Sequence Data | Acetylglucosamine - pharmacology | Aptamers, Nucleotide - immunology | Acetylglucosamine - chemistry | Drug Discovery | Streptococcus - drug effects | Epitopes - immunology | Animals | Anti-Bacterial Agents - immunology | Anti-Bacterial Agents - chemistry | Base Sequence | Antibodies, Bacterial - immunology | Streptococcal Infections - drug therapy | Anti-Bacterial Agents - pharmacology | Epitopes - chemistry | Streptococcal Infections - immunology | Complications and side effects | Bacterial infections | Immune response | Antibiotics | Physiological aspects | Dosage and administration |